Literature DB >> 18199896

Performance characteristics for some typical QT study designs under the ICH E-14 guidance.

Matthew M Hutmacher1, Sunny Chapel, Marilyn A Agin, Joseph C Fleishaker, Richard L Lalonde.   

Abstract

The International Conference on Harmonization (ICH) guidance for clinical evaluation of QT prolongation (E14) affected drug development by advocating that a thorough QT study (TQT) be conducted during development to assess the QT prolongation liability of a compound. The ICH E14 Statistics Group shortly thereafter recommended that a noninferiority intersection-union test (IUT) be used to exclude a clinically worrisome QT prolongation. Recent analyses have indicated that the IUT might be overly conservative with respect to excluding QT prolongation. This report assesses the IUT false positive rate for 4 recently conducted TQT trials using simple simulation experiments. Positive TQT study rates ranged from negligible to nearly 60% depending on study design, sample size, and patient status, despite no drug effect. Addition of clinically nonmeaningful QT prolongations (up to 5 milliseconds) increased the positive study rate to 80% for 1 particular study design. Ultimately, these results reveal significant limitations of the IUT with respect to excluding an effect and study interpretation for certain trial designs.

Entities:  

Mesh:

Year:  2008        PMID: 18199896     DOI: 10.1177/0091270007311921

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Comparing QT interval variability of semiautomated and high-precision ECG methodologies in seven thorough QT studies-implications for the power of studies intended for definitive evaluation of a drug's QT effect.

Authors:  Karin Meiser; Pierre Jordaan; Sasha Latypova; Borje Darpo
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-12-19       Impact factor: 1.468

Review 2.  Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

3.  Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study.

Authors:  Claus Graff; Johannes J Struijk; Jørgen K Kanters; Mads P Andersen; Egon Toft; Benoît Tyl
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

4.  Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.

Authors:  Puneet Gaitonde; Yeamin Huh; Borje Darpo; Georg Ferber; Günter Heimann; James Li; Kaifeng Lu; Bernard Sebastien; Kuenhi Tsai; Steve Riley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-30       Impact factor: 2.745

5.  Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Authors:  Shuying Yang; Misba Beerahee
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

Review 6.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

7.  Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Authors:  Rashmi Mehta; Michelle Green; Bela Patel; Jonathan Wagg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-01-06       Impact factor: 2.745

8.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

9.  Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model.

Authors:  Y Huh; M M Hutmacher
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.